Pancreatitis Trial, Recruiting NCT07330284 Sponsor: University of Kansas Medical Center Condition: Pancreatitis
Back to Pancreatitis

Pancreatitis Trial, Recruiting

NCT07330284
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You still have your natural bile duct opening (called a papilla) that has not been surgically altered.
  • You are already scheduled to have a procedure called ERCP (a procedure used to examine or treat the bile ducts and pancreas).
  • You are able to understand and sign a consent form agreeing to take part.

Who may not be able to join:

  • You have had stomach or intestinal surgery that significantly rerouted your digestive tract (except for one specific type called Billroth I — confirm with trial site).
  • You are currently having an episode of acute (sudden and severe) pancreatitis (inflammation of the pancreas) at the time of the procedure.
  • You have long-term (chronic) pancreatitis.
  • You have cancer of the head of the pancreas that is blocking the main pancreatic duct.
  • You already have a stent (small tube) in your pancreatic duct, or you are expected to need one placed during the procedure.
  • You are known to be allergic to, or cannot take, a pain-relief medicine called indomethacin or similar anti-inflammatory medicines (NSAIDs, such as ibuprofen).
  • Your kidneys are not working well enough (based on a specific blood test result — confirm with trial site).
  • You currently have, or have previously had, stomach ulcers or bleeding in your digestive system caused by anti-inflammatory medicines (NSAIDs).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Reza Hejazi, University of Kansas

Phone: 913-588-6019

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
5 December 2025
Est. completion
1 July 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Post-ERCP Pancreatitis (PEP) between the cold water and control groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov